Abstract
British Journal of Community NursingVol. 24, No. 11 TreatmentsResearch into glucose-lowering drugs for heart failure treatmentAysha MendesAysha MendesE-mail Address: [email protected]Freelance journalist specialising in healthcare and psychologySearch for more papers by this authorAysha MendesPublished Online:1 Nov 2019https://doi.org/10.12968/bjcn.2019.24.11.560AboutSectionsView articleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareShare onFacebookTwitterLinked InEmail View article References National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management [NG106]. 2018. www.nice.org.uk/guidance/ng106 (accessed 24 October 2019) Google ScholarNeal B, Perkovic V, Mahaffey KW et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377:644–657. https://doi.org/10.1056/NEJMoa1611925 Crossref, Medline, Google ScholarNHS. Overview: heart failure. 2018. https://www.nhs.uk/conditions/heartfailure/ (accessed 18 October 2019) Google ScholarPasternak B, Ueda P, Eliasson et al. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ. 2019; 366:l4772. https://doi.org/10.1136/bmj.l4772 Crossref, Medline, Google ScholarRushton CA, Kadam UT. Polypharmacy in heart failure: a growing challenge. Br J Cardiac Nurs. 2011; 6(5):214–220. https://doi.org/10.12968/bjca.2011.6.5.214 Link, Google ScholarSharp J, McCowat M. Depression in heart failure. Br J Cardiac Nurs. 2019; 14(6):1–11. https://doi.org/10.12968/bjca.2019.0011 Link, Google ScholarWiviott SD, Raz I, Bonaca MP et al.; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380:347–357. https://doi.org/10.1056/NEJMoa1812389 Crossref, Medline, Google ScholarZelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393:31–39. https://doi.org/10.1016/S0140-6736(18)32590-X Crossref, Medline, Google ScholarZinman B, Wanner C, Lachin JM et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720 Crossref, Medline, Google Scholar FiguresReferencesRelatedDetails 2 November 2019Volume 24Issue 11ISSN (print): 1462-4753ISSN (online): 2052-2215 Metrics History Published online 1 November 2019 Published in print 2 November 2019 Information© MA Healthcare LimitedPDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
